Long-term outcomes after stepping down asthma controller medications: A claims-based, time-to-event analysis

Matthew A Rank, Ryan Johnson, Megan Branda, Jeph Herrin, Holly Van Houten, Michael R. Gionfriddo, Nilay D Shah

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: Long-term outcomes after stepping down asthma medications are not well described. METHODS: This study was a retrospective time-to-event analysis of individuals diagnosed with asthma who stepped down their asthma controller medications using a US claims database spanning 2000 to 2012. Four-month intervals were established and a step-down event was defined by a ≥ 50% decrease in days-supplied of controller medications from one interval to the next; this definition is inclusive of step-down that occurred without health-care provider guidance or as a consequence of a medication adherence lapse. Asthma stability in the period prior to step-down was defined by not having an asthma exacerbation (inpatient visit, ED visit, or dispensing of a systemic corticosteroid linked to an asthma visit) and having fewer than two rescue inhaler claims in a 4-month period. The primary outcome in the period following stepdown was time-to-first asthma exacerbation. RESULTS: Thirty-two percent of the 26,292 included individuals had an asthma exacerbation in the 24-month period following step-down of asthma controller medication, though only 7% had an ED visit or hospitalization for asthma. The length of asthma stability prior to stepping down asthma medication was strongly associated with the risk of an asthma exacerbation in the subsequent 24-month period: < 4 months' stability, 44%; 4 to 7 months, 34%; 8 to 11 months, 30%; and ≥ 12 months, 21% ( P < .001). CONCLUSIONS: In a large, claims-based, real-world study setting, 32% of individuals have an asthma exacerbation in the 2 years following a step-down event.

Original languageEnglish (US)
Pages (from-to)630-639
Number of pages10
JournalChest
Volume148
Issue number3
DOIs
StatePublished - Sep 1 2015

Fingerprint

Asthma
Medication Adherence
Nebulizers and Vaporizers
Health Personnel
Inpatients
Adrenal Cortex Hormones
Hospitalization
Databases

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Long-term outcomes after stepping down asthma controller medications : A claims-based, time-to-event analysis. / Rank, Matthew A; Johnson, Ryan; Branda, Megan; Herrin, Jeph; Van Houten, Holly; Gionfriddo, Michael R.; Shah, Nilay D.

In: Chest, Vol. 148, No. 3, 01.09.2015, p. 630-639.

Research output: Contribution to journalArticle

Rank, Matthew A ; Johnson, Ryan ; Branda, Megan ; Herrin, Jeph ; Van Houten, Holly ; Gionfriddo, Michael R. ; Shah, Nilay D. / Long-term outcomes after stepping down asthma controller medications : A claims-based, time-to-event analysis. In: Chest. 2015 ; Vol. 148, No. 3. pp. 630-639.
@article{27ff14858be846b5814209c3258fc119,
title = "Long-term outcomes after stepping down asthma controller medications: A claims-based, time-to-event analysis",
abstract = "BACKGROUND: Long-term outcomes after stepping down asthma medications are not well described. METHODS: This study was a retrospective time-to-event analysis of individuals diagnosed with asthma who stepped down their asthma controller medications using a US claims database spanning 2000 to 2012. Four-month intervals were established and a step-down event was defined by a ≥ 50{\%} decrease in days-supplied of controller medications from one interval to the next; this definition is inclusive of step-down that occurred without health-care provider guidance or as a consequence of a medication adherence lapse. Asthma stability in the period prior to step-down was defined by not having an asthma exacerbation (inpatient visit, ED visit, or dispensing of a systemic corticosteroid linked to an asthma visit) and having fewer than two rescue inhaler claims in a 4-month period. The primary outcome in the period following stepdown was time-to-first asthma exacerbation. RESULTS: Thirty-two percent of the 26,292 included individuals had an asthma exacerbation in the 24-month period following step-down of asthma controller medication, though only 7{\%} had an ED visit or hospitalization for asthma. The length of asthma stability prior to stepping down asthma medication was strongly associated with the risk of an asthma exacerbation in the subsequent 24-month period: < 4 months' stability, 44{\%}; 4 to 7 months, 34{\%}; 8 to 11 months, 30{\%}; and ≥ 12 months, 21{\%} ( P < .001). CONCLUSIONS: In a large, claims-based, real-world study setting, 32{\%} of individuals have an asthma exacerbation in the 2 years following a step-down event.",
author = "Rank, {Matthew A} and Ryan Johnson and Megan Branda and Jeph Herrin and {Van Houten}, Holly and Gionfriddo, {Michael R.} and Shah, {Nilay D}",
year = "2015",
month = "9",
day = "1",
doi = "10.1378/chest.15-0301",
language = "English (US)",
volume = "148",
pages = "630--639",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Long-term outcomes after stepping down asthma controller medications

T2 - A claims-based, time-to-event analysis

AU - Rank, Matthew A

AU - Johnson, Ryan

AU - Branda, Megan

AU - Herrin, Jeph

AU - Van Houten, Holly

AU - Gionfriddo, Michael R.

AU - Shah, Nilay D

PY - 2015/9/1

Y1 - 2015/9/1

N2 - BACKGROUND: Long-term outcomes after stepping down asthma medications are not well described. METHODS: This study was a retrospective time-to-event analysis of individuals diagnosed with asthma who stepped down their asthma controller medications using a US claims database spanning 2000 to 2012. Four-month intervals were established and a step-down event was defined by a ≥ 50% decrease in days-supplied of controller medications from one interval to the next; this definition is inclusive of step-down that occurred without health-care provider guidance or as a consequence of a medication adherence lapse. Asthma stability in the period prior to step-down was defined by not having an asthma exacerbation (inpatient visit, ED visit, or dispensing of a systemic corticosteroid linked to an asthma visit) and having fewer than two rescue inhaler claims in a 4-month period. The primary outcome in the period following stepdown was time-to-first asthma exacerbation. RESULTS: Thirty-two percent of the 26,292 included individuals had an asthma exacerbation in the 24-month period following step-down of asthma controller medication, though only 7% had an ED visit or hospitalization for asthma. The length of asthma stability prior to stepping down asthma medication was strongly associated with the risk of an asthma exacerbation in the subsequent 24-month period: < 4 months' stability, 44%; 4 to 7 months, 34%; 8 to 11 months, 30%; and ≥ 12 months, 21% ( P < .001). CONCLUSIONS: In a large, claims-based, real-world study setting, 32% of individuals have an asthma exacerbation in the 2 years following a step-down event.

AB - BACKGROUND: Long-term outcomes after stepping down asthma medications are not well described. METHODS: This study was a retrospective time-to-event analysis of individuals diagnosed with asthma who stepped down their asthma controller medications using a US claims database spanning 2000 to 2012. Four-month intervals were established and a step-down event was defined by a ≥ 50% decrease in days-supplied of controller medications from one interval to the next; this definition is inclusive of step-down that occurred without health-care provider guidance or as a consequence of a medication adherence lapse. Asthma stability in the period prior to step-down was defined by not having an asthma exacerbation (inpatient visit, ED visit, or dispensing of a systemic corticosteroid linked to an asthma visit) and having fewer than two rescue inhaler claims in a 4-month period. The primary outcome in the period following stepdown was time-to-first asthma exacerbation. RESULTS: Thirty-two percent of the 26,292 included individuals had an asthma exacerbation in the 24-month period following step-down of asthma controller medication, though only 7% had an ED visit or hospitalization for asthma. The length of asthma stability prior to stepping down asthma medication was strongly associated with the risk of an asthma exacerbation in the subsequent 24-month period: < 4 months' stability, 44%; 4 to 7 months, 34%; 8 to 11 months, 30%; and ≥ 12 months, 21% ( P < .001). CONCLUSIONS: In a large, claims-based, real-world study setting, 32% of individuals have an asthma exacerbation in the 2 years following a step-down event.

UR - http://www.scopus.com/inward/record.url?scp=84941670851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941670851&partnerID=8YFLogxK

U2 - 10.1378/chest.15-0301

DO - 10.1378/chest.15-0301

M3 - Article

C2 - 25997080

AN - SCOPUS:84941670851

VL - 148

SP - 630

EP - 639

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -